In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and IR870 infrared dye antibody conjugates. For the ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for the ...